Doxorubicin treatment inhibits PPARγ and may induce lipotoxicity by mimicking a type 2 diabetes-like condition in rodent models

FEBS Letters

Volumn 587, Issue 2, 2013, Pages 105-110

  Arunachalam, Sankarganesh ^a   Tirupathi Pichiah, P B ^b   Achiraman, Shanmugam ^a  

^a BHARATHIDASAN UNIVERSITY   (India)

^b Chonbuk National University   (South Korea)

Author keywords

Adipogenesis; Adipose tissue inflammation; Doxorubicin; PPAR ; Type 2 diabetes

Indexed keywords

DOXORUBICIN; FATTY ACID TRANSPORTER; GLUCOSE; GLUCOSE TRANSPORTER; INSULIN; KRUPPEL LIKE FACTOR 4; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOGENESIS; ADIPOSE TISSUE; ADVERSE OUTCOME; ARTICLE; BIOACCUMULATION; BODY WEIGHT; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOWN REGULATION; GENE; GLUCOSE BLOOD LEVEL; GLUCOTOXICITY; HYPERGLYCEMIA; HYPERLIPIDEMIA; INFLAMMATION; INSULIN RESISTANCE; KLF4 GENE; LIPID ABSORPTION; LIPID BLOOD LEVEL; LIPOTOXICITY; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TOXICITY; UPREGULATION;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DOXORUBICIN; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIPIDS; METABOLIC NETWORKS AND PATHWAYS; MICE; MODELS, BIOLOGICAL; PPAR GAMMA;

ANIMALIA; RODENTIA;

EID: 84872115843     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2012.11.019     Document Type: Article

References (78)

1. A. Di Marco, M. Gaetani, and B. Scarpinato Adriamycin (NSC-123,127): a new antibiotic with antitumor activity Cancer Chemother. Rep. 53 1969 33 37
2. F.A. Fornari, J.K. Randolph, J.C. Yalowich, M.K. Ritke, and D.A. Gewirtz Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells Mol. Pharmacol. 45 1994 649 656
3. R.L. Momparler, M. Karon, S.E. Siegel, and F. Avila Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells Cancer Res. 36 1976 2891 2895
4. P.B. Tirupathi Pichiah Adriamycin induced spermatogenesis defect is due to the reduction in epididymal adipose tissue mass: a possible hypothesis Med. Hypotheses 78 2012 218 220
5. P. Xiang Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model Cancer Chemother. Pharmacol. 63 2009 343 349
6. R.B. Kelishomi, S. Ejtemaeemehr, S.M. Tavangar, R. Rahimian, J.I. Mobarakeh, and A.R. Dehpour Morphine is protective against doxorubicin-induced cardiotoxicity in rat Toxicology 243 2008 96 104
7. R.V. Santos, M.L. Batista Jr., E.C. Caperuto, and L.F. Costa Rosa Chronic supplementation of creatine and vitamins C and E increases survival and improves biochemical parameters after Doxorubicin treatment in rats Clin. Exp. Pharmacol. Physiol. 34 2007 1294 1299
8. Y. Xu, Z. Liu, J. Sun, Q. Pan, F. Sun, Z. Yan, and X. Hu Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo PLoS ONE 6 2011 e28335
9. H.I. El-Sayyad, M.F. Ismail, F.M. Shalaby, R.F. Abou-El-Magd, R.L. Gaur, A. Fernando, M.H. Raj, and A. Ouhtit Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats Int. J. Biol. Sci. 5 2009 466 473
10. B.C. Koti, A.H. Vishwanathswamy, J. Wagawade, and A.H. Thippeswamy Cardioprotective effect of lipistat against doxorubicin induced myocardial toxicity in albino rats Indian J. Exp. Biol. 47 2009 41 46
11. N. Iliskovic, and P.K. Singal Lipid lowering: an important factor in preventing adriamycin-induced heart failure Am. J. Pathol. 150 1997 727 734
12. N. Venkatesan, P. Venkatesan, J. Karthikeyan, and V. Arumugam Protection by taurine against adriamycin-induced proteinuria and hyperlipidemia in rats Proc. Soc. Exp. Biol. Med. 215 1997 158 164
13. Y.M. Hong, H.S. Kim, and H.R. Yoon Serum lipid and fatty acid profiles in adriamycin-treated rats after administration of l-carnitine Pediatr. Res. 51 2002 249 255
14. A. Geetha, J. Catherine, and C.S. Shyamala Devi Effect of α-tocopherol on doxorubicin induced alterations in glucose metabolism - A pilot study J. Biosci. 14 1989 243 247
15. S.R. Khan, N. Ayub, S. Nawab, and T.S. Shamsi Triglyceride profile in dyslipidaemia of type 2 diabetes mellitus J. Coll. Physicians Surg. Pak. 18 2008 270 273
16. Maria P. Solano, and Ronald B. Goldberg Lipid management in type 2 diabetes Clin. Diabetes 24 2006 6
17. L. Gordon, D. Ragoobirsingh, E.Y. Morrison, E. Choo-Kang, D. McGrowder, and E. Martorell Lipid profile of type 2 diabetic and hypertensive patients in the Jamaican population J. Lab. Physicians 2 2010 25 30
18. S. Sapna, and M.L. Alok A study on lipid profile levels of diabetics and non-diabetics among Naini Region of Allahabad, India Turk. J. Biochem 33 2008 4
19. G. Jiang Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists Diabetes 51 2002 2412 2419
20. M. Laplante, H. Sell, K.L. MacNaul, D. Richard, J.P. Berger, and Y. Deshaies PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion Diabetes 52 2003 291 299
21. N.D. Oakes, P.G. Thalen, S.M. Jacinto, and B. Ljung Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability Diabetes 50 2001 1158 1165
22. 14-palmitic acid labeled chylomicrons in rats Acta Physiol. Scand. 55 1962 170 176
23. A.M. Lefebvre Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates Arterioscler. Thromb. Vasc. Biol. 17 1997 1756 1764
24. P.G. McTernan Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro Diabetes 51 2002 1493 1498
25. W. Wahli, O. Braissant, and B. Desvergne Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more Chem. Biol. 2 1995 261 266
26. F. Picard, and J. Auwerx PPAR(gamma) and glucose homeostasis Annu. Rev. Nutr. 22 2002 167 197
27. W. Liao, M.T. Nguyen, T. Yoshizaki, S. Favelyukis, D. Patsouris, T. Imamura, I.M. Verma, and J.M. Olefsky Suppression of PPAR-gamma attenuates insulin-stimulated glucose uptake by affecting both GLUT1 and GLUT4 in 3T3-L1 adipocytes Am. J. Physiol. Endocrinol. Metab. 293 2007 E219 27
28. Z. Wu, Y. Xie, R.F. Morrison, N.L. Bucher, and S.R. Farmer PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes J. Clin. Invest. 101 1998 22 32
29. P. Tontonoz, E. Hu, R.A. Graves, A.I. Budavari, and B.M. Spiegelman MPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer Genes Dev. 8 1994 1224 1234
30. A. Vidal-Puig, M. Jimenez-Linan, B.B. Lowell, A. Hamann, E. Hu, B. Spiegelman, J.S. Flier, and D.E. Moller Regulation of PPAR gamma gene expression by nutrition and obesity in rodents J. Clin. Invest. 97 1996 2553 2561
31. Y.T. Kruszynska, R. Mukherjee, L. Jow, S. Dana, J.R. Paterniti, and J.M. Olefsky Skeletal muscle peroxisome proliferator-activated receptor-gamma expression in obesity and non-insulin-dependent diabetes mellitus J. Clin. Invest. 101 1998 543 548
32. V. Simha, and A. Garg Lipodystrophy: lessons in lipid and energy metabolism Curr. Opin. Lipidol. 17 2006 162 169
33. M.E. Rinella, M.S. Elias, R.R. Smolak, T. Fu, J. Borensztajn, and R.M. Green Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet J. Lipid Res. 49 2008 1068 1076
34. L. Chao, B. Marcus-Samuels, M.M. Mason, J. Moitra, C. Vinson, E. Arioglu, O. Gavrilova, and M.L. Reitman Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones J. Clin. Invest. 106 2000 1221 1228
35. P.D. Miles, Y. Barak, W. He, R.M. Evans, and J.M. Olefsky Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency J. Clin. Invest. 105 2000 287 292
36. R. Nakano, E. Kurosaki, S. Yoshida, M. Yokono, A. Shimaya, T. Maruyama, and M. Shibasaki Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo Biochem. Pharmacol. 72 2006 42 52
37. M. Guerre-Millo PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance Diabetes 50 2001 2809 2814
38. B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr. Rev. 20 1999 649 688
39. J.R. Jones Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance Proc. Natl. Acad. Sci. USA 102 2005 6207 6212
40. B. Lecka-Czernik Aleglitazar, a dual PPARalpha and PPARgamma agonist for the potential oral treatment of type 2 diabetes mellitus IDrugs 13 2010 793 801
41. Y. Zhou Peroxisome proliferator-activated receptor-alpha is renoprotective in doxorubicin-induced glomerular injury Kidney Int. 79 2011 1302 1311
42. P. Tontonoz, E. Hu, and B.M. Spiegelman Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor Cell 79 1994 1147 1156
43. J.P. Frias, J.G. Yu, Y.T. Kruszynska, and J.M. Olefsky Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects Diabetes Care 23 2000 64 69
44. Y. Miyazaki Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone Diabetes Care 24 2001 710 719
45. J.J. Nolan, B. Ludvik, P. Beerdsen, M. Joyce, and J. Olefsky Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone N. Engl. J. Med. 331 1994 1188 1193
46. M. Agostini Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance Cell Metab. 4 2006 303 311
47. F.E. Yakubu-Madus, T.W. Stephens, and W.T. Johnson Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione Diabetes Obes. Metab. 2 2000 155 163
48. C.J. de Souza, M. Eckhardt, K. Gagen, M. Dong, W. Chen, D. Laurent, and B.F. Burkey Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance Diabetes 50 2001 1863 1871
49. T. Yamauchi The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance J. Biol. Chem. 276 2001 41245 41254
50. H.M. Wright, C.B. Clish, T. Mikami, S. Hauser, K. Yanagi, R. Hiramatsu, C.N. Serhan, and B.M. Spiegelman A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation J. Biol. Chem. 275 2000 1873 1877
51. N.A. Abumrad, M.R. el-Maghrabi, E.Z. Amri, E. Lopez, and P.A. Grimaldi Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36 J. Biol. Chem. 268 1993 17665 17668
52. H.J. Lim, S. Lee, K.S. Lee, J.H. Park, Y. Jang, E.J. Lee, and H.Y. Park PPARgamma activation induces CD36 expression and stimulates foam cell like changes in rVSMCs Prostaglandins Other Lipid Mediat. 80 2006 165 174
53. K. Schoonjans, J. Peinado-Onsurbe, A.M. Lefebvre, R.A. Heyman, M. Briggs, S. Deeb, B. Staels, and J. Auwerx PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene EMBO J. 15 1996 5336 5348
54. T. Lemberger, B. Desvergne, and W. Wahli Peroxisome proliferator- activated receptors: a nuclear receptor signaling pathway in lipid physiology Annu. Rev. Cell Dev. Biol. 12 1996 335 363
55. G. Medina-Gomez PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism PLoS Genet. 3 2007 e64
56. N. Irwin, J.M. McKinney, C.J. Bailey, N.H. McClenaghan, and P.R. Flatt Acute and long-term effects of peroxisome proliferator-activated receptor-gamma activation on the function and insulin secretory responsiveness of clonal beta-cells Horm. Metab. Res. 43 2011 244 249
57. J.S. Harmon, C.E. Gleason, Y. Tanaka, E.A. Oseid, K.K. Hunter-Berger, and R.P. Robertson In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression Diabetes 48 1999 1995 2000
58. J.E. Schaffer Lipotoxicity: when tissues overeat Curr. Opin. Lipidol. 14 2003 281 287
59. R.H. Unger, and Y.T. Zhou Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover Diabetes 50 Suppl. 1 2001 S118 S121
60. R.A. DeFronzo Dysfunctional fat cells, lipotoxicity and type 2 diabetes Int. J. Clin. Pract. Suppl. 2004 9 21
61. Y.P. Zhou, and V. Grill Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans J. Clin. Endocrinol. Metab. 80 1995 1584 1590
62. M. Prentki, S. Vischer, M.C. Glennon, R. Regazzi, J.T. Deeney, and B.E. Corkey Malonyl-CoA and long chain acyl-CoA esters as metabolic coupling factors in nutrient-induced insulin secretion J. Biol. Chem. 267 1992 5802 5810
63. P.T. Clayton Hyperinsulinism in short-chain l-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion J. Clin. Invest. 108 2001 457 465
64. R.H. Unger, and L. Orci Diseases of liporegulation: new perspective on obesity and related disorders FASEB J. 15 2001 312 321
65. H. Shi, M.V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J.S. Flier TLR4 links innate immunity and fatty acid-induced insulin resistance J. Clin. Invest. 116 2006 3015 3025
66. M.T. Nguyen A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via toll-like receptors 2 and 4 and JNK-dependent pathways J. Biol. Chem. 282 2007 35279 35292
67. K. Cusi The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes Curr. Diab. Rep. 10 2010 306 315
68. J.G. Neels, and J.M. Olefsky Inflamed fat: what starts the fire? J. Clin. Invest. 116 2006 33 35
69. M.J. Yin, Y. Yamamoto, and R.B. Gaynor The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta Nature 396 1998 77 80
70. M. Yuan, N. Konstantopoulos, J. Lee, L. Hansen, Z.W. Li, M. Karin, and S.E. Shoelson Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta Science 293 2001 1673 1677
71. J.K. Kim, O. Gavrilova, Y. Chen, M.L. Reitman, and G.I. Shulman Mechanism of insulin resistance in A-ZIP/F-1 fatless mice J. Biol. Chem. 275 2000 8456 8460
72. G.W. Cline Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes N. Engl. J. Med. 341 1999 240 246
73. O. Gavrilova Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice J. Clin. Invest. 105 2000 271 278
74. S. Kamohara, R. Burcelin, J.L. Halaas, J.M. Friedman, and M.J. Charron Acute stimulation of glucose metabolism in mice by leptin treatment Nature 389 1997 374 377
75. K.T. Uysal, S.M. Wiesbrock, M.W. Marino, and G.S. Hotamisligil Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function Nature 389 1997 610 614
76. S. Arunachalam, S.Y. Kim, M.S. Kim, H.K. Yi, B.S. Yun, D.Y. Lee, and P.H. Hwang Adriamycin inhibits adipogenesis through the modulation of PPARgamma and restoration of adriamycin-mediated inhibition of adipogenesis by PPARgamma over-expression Toxicol. Mech. Methods 22 2012 540 546
77. K. Birsoy, Z. Chen, and J. Friedman Transcriptional regulation of adipogenesis by KLF4 Cell Metab. 7 2008 339 347
78. Q. Zhou, Y. Hong, Q. Zhan, Y. Shen, and Z. Liu Role for Kruppel-like factor 4 in determining the outcome of p53 response to DNA damage Cancer Res. 69 2009 8284 8292